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Summary The outcome of salvage treatment was reviewed in 55 patients relapsing during or after their
primary chemotherapy for advanced malignant germ cell tumours. Fifty-two patients had been given cisplatin-
based chemotherapy as their primary treatment, whereas three patients had received carboplatin-based
chemotherapy. The median time to relapse was 2 months (range: 0-96 months) from discontinuation of the
primary treatment. Two patients underwent radical surgery only, and one patient had radiotherapy to a brain
metastasis as his only curatively intended salvage treatment. Six patients did not receive any treatment for
their recurrent malignancy (refusal, terminal condition) except for purely palliative measures. The disease-free
survival for the total group was 27% at 5 years. Complete response to primary treatment lasting for > 6
months was the only parameter which significantly predicted a favourable outcome (45% 5 year disease-free
survival in 12 eligible patients).
Using cisplatin-based chemotherapy in the primary treatment
of patients with disseminated germ cell tumours a 80-85% 5
year survival is achieved (Stoter et al., 1986; Williams et al.,
1987; Aass et al., 1990; Dearnaley et al., 1991). However,
about 15% of all patients relapse after their initial treatment
and need effective salvage treatment. The overall 5 years
survival in these patients has been reported to be between 20
to 30% with no clear advantage of any salvage regimen
(Motzer et al., 1991; Harstrick et al., 1991).
In the present retrospective study we review the results of
salvage treatment in patients with malignant germ cell
tumours who have been treated at the Norwegian Radium
Hospital (NRH) for relapse after the primary treatment with
cisplatin or carboplatin-based combination chemotherapy.
Particular emphasis is put on identification of prognostic
factors which are correlated with favourable long term sur-
vival.
Patients and methods
Patients
From 1981 to 1991 55 of 405 patients with disseminated
germ cell tumours developed signs of disease relapse after or
during their primary cisplatin/carboplatin-based chemo-
therapy. The definition of relapse implied increase of alpha
foetoprotein (AFP) and/or human choriogonadotropin
(HCG), size increase of an existing metastasis and/or the
development of a new lesion. Patients without these condi-
tions in whom residual vital malignant tumour tissue was
found in the routinely obtained post-chemotherapy operation
specimen were thus excluded. Twelve patients had extra-
gonadal and 43 testicular germ cell tumours (Table I). Forty-
six per cent of the patients initially presented with 'very large
volume' disease (Medical Research Council Working Party
Report on Testicular Tumours, 1985).
Primary treatment
Up to 1985 the PVB regimen (Cisplatin 100 mg m-2, Vinblas-
tine 0.20-0.30 mg kg-', Bleomycin 90 mg) represented the
initial treatment schedule with subsequent gradual shift to
the BEP 20 regimen (Bleomycin 90mg, Etoposide 360-500
Table I Patient characteristics
No of patients
Age (years)
Site
Testicular
Extragonadal
Histology
Seminoma
Non-seminoma
Not classifiable
Stage
IC
2
3
4
Risk groups
Small volume
Large volume
Very large volume
Tumour markers
AFP + HCG normal
HCG <10000U 1' and AFP <1000 gl-l
HCG >10000 U '-' and/or AFP > I000fgl I
55
31a (15-70)b
43
12
15
37
3
8
10
36
17
14
24
10
21
24
aMedian; bRange; CElevated AFP/HCG.
mg m 2, Cisplatin 100 mg mr-2) (Table II). Seven patients
primarily received high dose Cisplatin schedules (BEP40/60)
(Cisplatin 180 mg-200 mg m-2) (Fossa et al., 1990) and four
patients received BOP/VIP chemotherapy (Bleomycin, Onco-
vin, Cisplatin/Etoposide, [ = VP16] Ifosphamide Cisplatin.
Three patients were treated with other cisplatin-based com-
binations and three patients received CEB chemotherapy
(Carboplatin 400 mg m-2, Etoposide 360 mg m-2 and Bleo-
mycin 30 mg). All patients were to be treated by at least 4
three-weekly cycles if the disease did not progress earlier
during the treatment period. Patients with particularly high
tumour burden often received more than four treatment
cycles.
Dose reductions and treatment delays were performed as
indicated by clinical, hematological and biochemical toxicity.
The relative drug intensity (% of standard dosage) in an
individual patient was calculated assuming that 100mg m-2
Cisplatin and 500 mg m-2 VP-16 given within 3 weeks repre-
sented the standard dose (100%) (Longo et al., 1991).
Twenty-nine patients underwent post-chemotherapy sur-
gery, most often retroperitoneal lymph node dissection
(RLND). Four patients in whom vital malignant germ cell
cancer was found in the post-chemotherapy histological sec-
tion received three adjuvant chemotherapy cycles post-oper-
atively.
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Table II Primary treatment Table III Salvage chemotherapy
Type of chemotherapya
PVB
BEP 20 ± CVB
BEP 40/60
BOP/VIP
Other cisplatin combinations
CEB
No of cycles
2-3
4
5-6
>6
Relative drug intensity: cisplatin
No cisplatin
<75%
76-100
> 100%
Median (Range)
VP16
no VP16
<50%
> 50%
Median (Range)
Surgery
RLND
Thoracoth.
Other
No
Primary response
CR1 (necrosis or mat. ter. resected)
CR2 (vit. tumour resected)
PRI (no hist.)
PR2 (vit. tumour unresectable)
PD (Progr. before discont. of primary treatm.)
23
15
7
4
3
3
6
30
16
3
3
8
24
20
91 (41-216)
24
12
19
66 (13-116)
26
3
1
24
22
5
10
5
13
aCfr. text for abbreviations.
Response evaluation (primary treatment)
The following response criteria were used:
CR1: No residual tumour by clinical, radiological or bio-
chemical examinations and/or residual tumour contain-
ing complete necrosis or mature teratoma radically
resected.
CR2: Residual vital malignant tumour completely resected.
PRI: Partial remission clinically without histological
verification.
PR2: Partial remission clinically with histologically residual
but unresectable vital malignant tumour.
PD: Progression before discontinuation of scheduled pri-
mary treatment.
The progression-free interval was defined as the time span
between CR, PR or stable disease at the end of primary
chemotherapy and the diagnosis of relapse.
Primary chemotherapy resistance was consistent with PD
during the initial chemotherapy, or within 1 month after
treatment discontinuation.
Salvage treatment
In this retrospective series of 12 years multiple salvage treat-
ment schedules have been applied along with increasing
understanding of the tumour biology of this malignancy and
the availability of new drugs (Table III): During the first
years Etoposide + Ifosphamide (VI) have been used for sal-
vage treatment (5 patients). Later on high dose Cisplatin
regimens (six patients) or BEP20/EP chemotherapy (13 pa-
tients) (Etoposide 500 mg m-2 per cycle) have been applied if
PVB chemotherapy was given as primary treatment. (Maxi-
mal accumulated dose of Bleomycin: [including doses given
during initial chemotherapy] 360 mg). Combinations of
Etoposide Iphosphamide and cisplatin (VIP) were given to
seven patients. During the last 2 years BOP/VIP treatment
has been the first choice of salvage chemotherapy. Seven
patients were treated with chemotherapy regimens, contain-
ing neither cisplatin or iphosphamide, due to reduced renal
Type of chemotherapy/
No
PVB
BEP 20
BEP 40/60
Ifosfamide + Etoposide (VI)
VIP
BOP/VIP
Other
No of cycles
1-2
3-4
5-6
Dose-limiting toxicity
No
Leukopenia
Thrombopenia
Leukopenia + thrombopenia
Nephrotoxicity
Nephrotoxicity + myelosuppression
Status
Alive NED
Alive with disease
Dead of treatment-related toxicity NED
Dead from/with disease
aCfr. text for abbreviations.
9
1
13
6
5
7
6
8
14
24
8
10
13
2
17
1
3
18
3
33
function before start of salvage treatment. They received
carboplatin combinations (two patients), alkylating drugs/
drug combinations (four patients) or experimental treatment
within phase II trials (two patients). Finally, nine patients did
not receive any systemic treatment either due to refusal (five)
or as they came to the oncological unit in a terminal condi-
tion (two). In the eighth patient, the histopathological
examination of a retroperitoneal tumour which occurred 13
months after RLND showed mature teratoma. In the ninth
patient a growing lung density was diagnosed 8 years after
initial treatment. Thoracotomy was performed and completely
necrotic metastatic tumour tissue was resected. No chemo-
therapy was given to the latter two patients. In one of the
five patients who refused further chemotherapy, high-dose
radiotherapy was given to a brain metastasis, which was the
only manifestation of relapse. This patient is currently alive
for 4 years without evidence of disease.
Most patients received between two and four cycles of
chemotherapy depending on development of the disease and
toxicity. Fourteen patients underwent surgery as part of their
salvage treatment (RLND: six, Thoracotomy: seven, Other:
one). Fourteen patients had radiotherapy, most often given
with palliative intention.
Follow-up
As a rule patients underwent bi-monthly clinical, radiological
and biochemical examinations during the first year after dis-
continuation of their treatment, later on with increasing
intervals. All patients were followed until death or until May
1st 1992 (medial observation time from start of salvage treat-
ment for surviving patients: 48 months; range 2-119
months).
Statistics
All calculations were made by the PC based 'Medlog' prog-
ram, applying common statistical procedures (Median, Fisher
exact probability test, Kaplan Meier survival analysis, Log-
rank test). A P-value <0.05 was regarded as statistically
significant.
Results
In 23 patients the re-activation of the malignancy presented
as increase of serum alpha-foetoprotein (AFP) and/or of570 D. JOSEFSEN et al.
human choriogonadotropin (HCG). In 16 patients lung me-
tastases or retroperitoneal lymph node metastases increased
in size, whereas seven developed growing mediastinal mani-
festations. Brain metastases occurred in five patients and
bone or liver metastases in four patients.
The median progression-free interval was only 2 months
(Range: 0-96 months). In 17 patients 6 months or more
elapsed after the end of primary treatment. Primary chemo-
therapy resistance was observed in 24 patients.
Response
Second line chemotherapy resulted in > 50% tumour marker
decrease in 28 patients and > 50% tumour reduction in 15
patients. In 33 patients the disease reactivated during or after
the first salvage chemotherapy with a median of 4 months
from start of salvage treatment (Range 1-60 months). Three
of these patients are currently alive with active disease after
4, 8 and 10 months after their second relapse. A fourth
patient is tumour-free 11 years after extirpation of a lung
metastasis, which increased in size in spite of second-line
chemotherapy. The remaining 29 patients with relapse after
second-line treatment are dead.
Third line chemotherapy was given to 19 patients often
within phase II studies. In nqne of these patients a durable
CR was achieved.
Table IV 5 year survival after start of salvage treatment (Univariate
analysis)
No of
Patients Survival P-value
Age
< 35 years 32 25%
>35 years 23 22% 0.708
Extent of the disease
Small volume 17 36%
Large volume 14 18% 0.2600
Very large volume 24 26% 0.598
Type of chemotherapy
PVB 24 24%
VP-16 containing chemoth. 31 22% 0745
Relative cisplatin-intensity
<100% 35 21% 0899
> 100% 20 32%
Response to primary treatment
CR1 22 31% 009 <CR 1 33 20% 0.097
Progression-free interval
<6 months 38 22%
>6 months 17 41% 0.051
Type ofprimary response/duration of progression-free interval'
CR 1 for > 6 months 12 45%
<CR I and/or <6 months 37 22% 0.041
aOnly patients in whom salvage treatment with curative intention
was given.
Survival
At the end of the observation time 17 patients are alive
without evidence of disease. Three additional patients are
alive with progressing germ cell malignancy. The 5 year
disease-free survival for all relapsing patients was 27%
(Figure la). Most patients with disease reactivation after
salvage chemotherapy died within the first 2 years after their
relapse, though 2 patients survived for more than 3 years.
Achievement of a CR1 during primary treatment and a
relapse-free interval of > 6 months were associated with a
favourable disease-free survival (P: 0.097 and 0.051, respec-
tively) (Table IV). The combination of these two parameters
was associated with a 38% 5 year disease-free survival
(Figure lb) (P: 0.041). The intensity of primary cisplatin
100
80
> 60
a 40
O)
a
O
8*
treatment (relative cisplatin dose > 100% vs < 100%) was
not associated with the long-term outcome of salvage ther-
apy. Patients receiving PVB as their primary treatment had a
similar survival as those who initially had VP-16 containing
chemotherapy. The initial tumour burden or age did neither
have any impact on the final outcome after second line
treatment.
Table V summarises the clinical course of those 14 patients
who were alive > 12 months after start of salvage treatment.
In nine, surgery was a part of salvage treatment and three
patients received radiotherapy after second line chemo-
therapy.
a~~~~~b
0 25 50 75 0 25 50 75
Month since relapse
Figure 1 Disease-free survival in 55 patients with malignant germ cell tumours relapsing after cisplatin- or carboplatin-based
combination chemotherapy. a,All patients. b, Patients with CR after primary treatment lasting for > 6 months (upper curve) as
compared to patients not fulfilling this condition (lower curve) (P: 0.04). (Only patients with curatively intended salvage treatment).
*Number of patients under observation at 60 months.
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Table V Clinical course in patients with surviving for > 12 months after start of salvage treatment
Prim. Initial Response Relapse-free Other
site stagel Initial to init. interval Salvage salvage Obs. time
Id. no Histol MRC vol.b treatm.c treatm. (months) chemoth. treatm. (months)d
I test/ns 4/VLV PVB + RLND CRI 2 BEP 20 Thoracot. 119
2 test/ns 4/VLV PVB + BEP 40/60 CRI 21 BEP 40/60 Thoracot. 78
+ RLND
3 test/ns 3/LV PVB + Rlnd CR1 32 BEP 20 + Thoracot. 65
BEP 40/60
4 extrag/ns 3/SV PVB PD 1 BEP 20 RLND 89
5 test/ns 1Mark + CEB PD 1 BOP/VIP 27
/SV
6 test/ns 3/LV BOP/VIP PR2 5 CEB Thoracot. 23
+ RLND
7 extrag/ns 4/VLV BEP 20 + RLND CR1 29 BEP 40/60 BOP/VIP 68e
8 extrag/ns 4/VLV BEP 20 + RLND PRI 19 BEP 40/60 Thoracot. 55
9 test/s 4/VLV PVB + Radioth. CR1 35 BEP 20 Radioth. 79
10 test/s 2/LV PVB + Radioth. CR1 39 BEP 20 Radioth. 92
11 extrag/s 2/LV BEP 20 PR1 4 BOP/VIP RLND 46
+ Radioth.
12 test/s 4/LV PVB + Radioth. PRI 1 VACAf Thoracot. 90
13 test/ns 4/VLV BOP/VIP CR1 1 No Radioth. 50
14 test/ns 4/SV PVB + RLND CR1 96 No Thoracot. 14
an.s.: non-seminoma; s: seminoma: bRoyal Marsden Classification System: /Small volume (SV); Large volume (LV); Very large volume (VLV)
according to MRC: cCfr. test for abbreviations of the chemotherapy combinations; RLND: retroperitoneal lymph node dissection: dfrom start
of salvage treatment: eAlive with progressing disease, all other patients alive NED: fVincristine, doxorubicin, Cyclophosphamide, Actinomycin
C ().
Toxicity
Myelo-suppression was the most frequent toxicity during
salvage treatment, requiring dose reductions or delay of
scheduled chemotherapy. Nephrotoxicity (WHO grade > 2)
led to dose modifications of salvage treatment in four
patients. One patients who had relapsed with liver metas-
tases, died of neutropenic septicaemia after the second car-
boplatin- Etoposide cycle. At autopsy no metastases were
found.
Discussion
During salvage chemotherapy objective responses (significant
tumour marker decrease, > 50% reduction of tumour mas-
ses) were observed in the majority of patients, though these
remissions were often short-lasting. The overall disease-free
survival in our patients with malignant germ cell tumours
relapsing after initial cisplatin- or carboplatin-based chemo-
therapy was thus only 27%, which is comparable to reported
observations from other groups (Motzer et al., 1991; Har-
strick et al., 1991). The results of third line treatment are
even more dismal. In our opinion therapeutic trials after
failure of second line treatment should only be performed if
the oncologist and the patient have thoroughly considered all
cost-benefit aspects of such third line chemotherapy.
In our series only complete response after primary treat-
ment (without residual vital malignant germ cell tumour)
lasting for at least 6 months correlated with long-term sur-
vival after salvage chemotherapy. Patients fulfilling these
criteria, most probably have chemotherapy-sensitive tumours
and re-induction with intensive cisplatin-based chemotherapy
may be successful.
In the present series initial tumour burden did surprisingly
not have any influence on survival, contrary to observations
from the Royal Marsden Hospital (Gildersleve et al., 1991).
There was neither any correlation between the final out-come
and the primary chemotherapy (type, relative cisplatin-inten-
sity). We had expected that patients who initially had not at
all received etoposide or at less than maximal doses (100
mgm-2 per cycle) would respond particularly favourably to
salvage chemotherapy containing this drug at maximally
tolerated doses. The reason for the lack of such response may
be that almost all of our patients did receive cisplatin with
>75% intensity. Cisplatin is the most effective drug in
malignant germ cell tumours. If a patient is resistant to this
agent, salvage chemotherapy even though given with high
dose etoposide and/or ifosphamide only rarely leads to
durable CR. It should, however, be kept in mind that the
type II error in our series of only 55 patients is > 0.5, which
limits the general applicability of the results to a certain
degree.
During the last years carboplatin has been used more
frequently as first line cytostatic agent in malignant germ cell
tumours (Motzer et al., 1990; Horwich et al., 1991). It is too
early to decide what percentage of patients relapsing after
carboplatin treatment can be salvaged by secondary cisplatin-
based chemotherapy. Of our three patients relapsing after
initial carboplatin-based treatment a complete durable res-
ponse was achieved in only one patient (lasting for 27 +
months).
One of five patients (Table IV, No 13), who refused any
salvage chemotherapy had a durable complete response after
high-dose radiotherapy to a single brain metastasis. One
other patient (Table IV, No 1) relapsing after salvage chemo-
therapy was rendered permanently tumour-free by resection
of an increasing lung metastasis containing vital malignant
tumour tissue. Surgery and/or radiotherapy should always be
considered during salvage treatment of patients with germ
cell tumours. The importance of radiotherapy to brain metas-
tases has also been described by the Indiana Group (Spears
et al., 1991). Surgery may in selected cases be of critical
significance for the cure of patients resistant to salvage
chemotherapy (Cassidy et al., 1992).
In addition, surgery has an important diagnostic role in
patients with increasing tumour manifestations after their
initial cisplatin-based chemotherapy, in particular, if re-
growth of a lesion is diagnosed many months after the
primary treatment in a patient with normal levels of HCG
and AFP. In such cases histology often will reveal mature
teratoma or even completely necrotic tumour tissue, as in one
of our patients relapsing after 8 years. The growing teratoma
syndrome after chemotherapy has been described by several
authors (Basheda et al., 1991, Jansen et al., 1991) and
represents a condition which has to be treated surgically.
Late re-growth of residual completely necrotic metastasis has
not been reported previously.
In our series the development of nephrotoxicity was not a
major clinical problem during salvage chemotherapy and did
only rarely lead to dose reduction of the cytostatic agent or
treatment delay. Myelotoxicity, on the other hand, led to
frequent dose reductions and treatment delays. During the572 D. JOSEFSEN et al.
last year hematopoetic growth factors were applied in three
patients to avoid such dose modifications and to enable the
application of sufficient doses at short intervals. Other groups
have considered autologous bone marrow transplantation
(Eder et al., 1990; Broun et al., 1991; Droz et al., 1991) to
overcome myelotoxicity during high dose salvage
chemotherapy. However, so far no observations are available
proving that high or ultra high-dosed salvage chemotherapy
improves survival rates after salvage chemotherapy, in partic-
ular, when unselected patients are considered.
In conclusion, only about 25% of testicular cancer patients
relapsing after initial cisplatin-based chemotherapy survive
without evidence of disease for 3 years or more. These
overall disappointing results should be kept in mind when the
decision is made whether to treat an individual relapsing
patient or not, especially if the patient himself is reluctant to
further chemotherapy. CR to initial chemotherapy lasting for
at least 6 months is correlated with a favourable long-term
outcome. Radiotherapy and/or surgery are worthwhile addi-
tive treatment modalities and can in a few patients be critical
for the achievement of disease-free survivorship. Myelotox-
icity correlated with the risk of serious infections represented
the most frequent and most severe complication during sal-
vage treatment.
The study was financially supported by the Norwegian Cancer
Society.
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